Actively Recruiting
Leflunomide for Henoch-Schonlein Purpura
Led by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Updated on 2023-07-10
36
Participants Needed
1
Research Sites
234 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study conducted a prospective, multicenter, one-arm clinical trial on the combination of leflunomide and steroid therapy for refractory skin Henoch-Schonlein Purpura in children on the basis of ethical principles. A one-year follow-up was conducted to evaluate the changes in the main indicators (frequency of rash recurrence) and secondary indicators (proportion of kidney damage, proportion of joint involvement, T lymphocyte subpopulations, and inflammatory factors) before and after treatment, Exploring the safety and effectiveness of leflunomide in the treatment of refractory skin type HSP in children, it is expected that leflunomide combined with conventional treatment can improve the remission rate of HSP children's skin purpura and reduce HSP recurrence. The research results are expected to bring new treatment methods and strategies for this group of patients.
CONDITIONS
Official Title
Leflunomide for Henoch-Schonlein Purpura
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age ranges from 1 to 18 years old
- Patients meet the HSP diagnostic criteria
- Refractory skin type HSP with dense, large-area rashes not improving or recurring more than 3 times during hospitalization despite treatment with antibiotics, antihistamines, calcium supplements, and glucocorticoids (2 mg/kg/day) for 5 days
- Parents or guardians agree to treatment and sign a written informed consent form
You will not qualify if you...
- Allergy to leflunomide
- Severe underlying diseases such as systemic malignancy, heart failure, liver and kidney failure, immune deficiency, severe infections, organ transplant surgery, or current emergency surgery
- Presence of other digestive system diseases
- Prior use of flumiphene in clinical trials
- Purpura caused by drugs, infections, or other autoimmune diseases
- Other conditions deemed inappropriate for participation by the researcher
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China, 510120
Actively Recruiting
Research Team
H
Haiyan Wang, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here